A Phase I, Randomised, Double-blind, Placebo-controlled Study in Healthy Postmenopausal Women to Investigate the Safety, Tolerability, Food Effect and Pharmacokinetics of Single and Multiple Ascending Oral Doses of FOR-6219
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2018
At a glance
- Drugs FOR-6219 (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Sponsors Forendo Pharma
- 04 Jul 2018 Status changed from planning to recruiting, according to a Forendo Pharma media release.
- 04 Jul 2018 According to a Forendo Pharma media release, UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the clinical trial authorisation. Results are expected at end of 2018.
- 23 Mar 2018 New trial record